全文获取类型
收费全文 | 133239篇 |
免费 | 12224篇 |
国内免费 | 7020篇 |
专业分类
耳鼻咽喉 | 1311篇 |
儿科学 | 2323篇 |
妇产科学 | 1195篇 |
基础医学 | 10575篇 |
口腔科学 | 2770篇 |
临床医学 | 16695篇 |
内科学 | 14772篇 |
皮肤病学 | 2205篇 |
神经病学 | 4075篇 |
特种医学 | 4702篇 |
外国民族医学 | 22篇 |
外科学 | 11409篇 |
综合类 | 30159篇 |
现状与发展 | 29篇 |
一般理论 | 4篇 |
预防医学 | 14105篇 |
眼科学 | 2173篇 |
药学 | 16016篇 |
146篇 | |
中国医学 | 10744篇 |
肿瘤学 | 7053篇 |
出版年
2024年 | 490篇 |
2023年 | 1736篇 |
2022年 | 4293篇 |
2021年 | 5671篇 |
2020年 | 4691篇 |
2019年 | 3109篇 |
2018年 | 3247篇 |
2017年 | 3896篇 |
2016年 | 3341篇 |
2015年 | 5640篇 |
2014年 | 7455篇 |
2013年 | 8522篇 |
2012年 | 12379篇 |
2011年 | 12761篇 |
2010年 | 10672篇 |
2009年 | 9172篇 |
2008年 | 9650篇 |
2007年 | 9112篇 |
2006年 | 8528篇 |
2005年 | 6996篇 |
2004年 | 4882篇 |
2003年 | 4134篇 |
2002年 | 3313篇 |
2001年 | 2551篇 |
2000年 | 1978篇 |
1999年 | 1069篇 |
1998年 | 445篇 |
1997年 | 498篇 |
1996年 | 360篇 |
1995年 | 316篇 |
1994年 | 291篇 |
1993年 | 181篇 |
1992年 | 184篇 |
1991年 | 164篇 |
1990年 | 121篇 |
1989年 | 81篇 |
1988年 | 71篇 |
1987年 | 58篇 |
1986年 | 53篇 |
1985年 | 42篇 |
1984年 | 31篇 |
1983年 | 14篇 |
1982年 | 19篇 |
1980年 | 12篇 |
1979年 | 13篇 |
1965年 | 20篇 |
1959年 | 14篇 |
1958年 | 29篇 |
1957年 | 21篇 |
1956年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
树枝状静脉移植在手部创伤中的应用 总被引:3,自引:1,他引:2
目的探讨手掌严重碾挫伤应用血管移植手术方法的选择。方法对12例手掌碾挫伤伴血管损伤的患者,采用树枝状浅表静脉倒转后多级移植修复缺损的手掌动脉,同时对缺损皮肤一期行植皮或皮瓣修复。结果术后12例创面全部Ⅰ期愈合,手指血循环好。术后随访3~22个月,手功能评定: 优5例,良4例,可2例,差1例,优良率为75%。手掌恢复了良好的外形和功能,能完成手指的捏、握、对掌和对指功能。结论对严重的手掌毁损伤,利用树枝状静脉移植修复缺损的血管,能获得较好的手功能和外形。 相似文献
12.
Vincent Chung Liang Liu Zhaoxiang Bian Zhongzhen Zhao Wai Leuk Fong Wan Fung Kum Jing Gao Min Li 《Movement disorders》2006,21(10):1709-1715
The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted. 相似文献
13.
A. HAZIOT I. KATZ G. W. RONG X. Y. LIN J. SILVER & S. M. GOYERT 《Scandinavian journal of immunology》1997,46(3):242-245
Membrane-bound CD14 acts as a receptor for lipopolysaccharide (LPS) on monocytes/macrophages and neutrophils. Studies have suggested that the activation of monocytes/macrophages by the binding of LPS to membrane-bound CD14 may require the association of a signal-transducing molecule with membrane-bound CD14. The observation that non-CD14 expressing cells, such as endothelial cells, can nevertheless be activated by a complex of LPS and a soluble form of CD14 (sCD14) suggests that the receptor for this complex may be identical to the signal transducing molecule associated with membrane-bound CD14. The studies described show that two CD14-specific MoAb are able to block the LPS-induced activation of endothelial cells but do not affect the response of monocytes to LPS. This suggests that the interaction of the sCD14:LPS complex with endothelial cells is distinct from the interaction of membrane-bound CD14 with its putative signal-transducing molecule. 相似文献
14.
D.-Y. LIN I.-S. SHEEN C.-M. CHU & Y.-F. LIAW 《Alimentary pharmacology & therapeutics》1996,10(6):961-966
Background : The clinical course of chronic hepatitis B is variable. Patients with hepatic decompensation, bridging necrosis or an alpha-fetoprotein level greater than 100 ng/mL during an exacerbation of hepatitis have a high risk of developing cirrhosis. This study was conducted to evaluate the effect of colchicine in the prevention of cirrhosis in such patients.
Methods : Patients with risk factor(s) were randomized to receive either colchicine 5 mg/week or no specific treatment, the end point being development of cirrhosis.
Results : After a follow up period of 4 years, the treatment group had a marked reduction in exacerbations of acute hepatitis (32% vs. 63%/patient/year, P <0.005). Seven out of 38 patients in the treatment group and 10 out of 27 patients in the control group developed cirrhosis. The calculated cumulative incidence of cirrhosis by the end of first, second, third and fourth years in the treatment group was 8.7, 18.6, 32 and 32%, respectively. The corresponding figures in the control group were 30, 35.5, 46.3 and 73.2%, respectively, with a P -value of 0.057.
Conclusions : The results suggest that colchicine may prevent cirrhosis in chronic hepatitis B patients with risk factor(s), possibly by suppressing exacerbations of hepatitis through an anti-inflammatory effect. 相似文献
Methods : Patients with risk factor(s) were randomized to receive either colchicine 5 mg/week or no specific treatment, the end point being development of cirrhosis.
Results : After a follow up period of 4 years, the treatment group had a marked reduction in exacerbations of acute hepatitis (32% vs. 63%/patient/year, P <0.005). Seven out of 38 patients in the treatment group and 10 out of 27 patients in the control group developed cirrhosis. The calculated cumulative incidence of cirrhosis by the end of first, second, third and fourth years in the treatment group was 8.7, 18.6, 32 and 32%, respectively. The corresponding figures in the control group were 30, 35.5, 46.3 and 73.2%, respectively, with a P -value of 0.057.
Conclusions : The results suggest that colchicine may prevent cirrhosis in chronic hepatitis B patients with risk factor(s), possibly by suppressing exacerbations of hepatitis through an anti-inflammatory effect. 相似文献
15.
16.
目的 评价单克隆IgH基因重排检测在恶性淋巴瘤 (B NHL)临床中的应用价值。方法 用半巢式PCR检测单克隆IgH基因重排。病例组为B NHL ,包括 6 9例石蜡包埋组织切片、治疗前 16例骨髓和 2 9例外周血、阳性者治疗后复查骨髓和外周血 ;对照组为 10例慢性淋巴结炎、3例T NHL和 2例HD。结果 对照组均阴性。病例组 :切片中单克隆IgH基因重排阳性率为 6 3.8% (44 / 6 9) ;骨髓和外周血阳性率分别为 43 .8%(7/ 16 )和 41.4% (12 / 2 9) ,细胞形态学检查未见异常细胞者阳性率分别为 33 .3% (3/ 9)和 31.3% (5 / 16 )。 16例同时采集骨髓和外周血者 ,阳性率分别为 43 .8% (7/ 16 )和 37.5 % (6 / 16 ) ,两者无统计学差异。治疗前单克隆IgH重排阳性者 ,6例完全缓解 (CR)后转阴 ,处于持续缓解状态 ,1例临床缓解后 13个月仍阳性 ,现在继续随访中 ,另 1例CR后持续阳性者 ,6个月后复发。结论 切片、骨髓和外周血中检测单克隆IgH基因重排可以作为B NHL诊断和随访微小残留病灶的辅助手段 相似文献
17.
膳食黑米皮抑制高脂诱导的家兔动脉粥样硬化形成及其机制的初步探讨 总被引:1,自引:0,他引:1
目的 探讨膳食黑米皮对高脂诱导的家兔动脉粥样硬化形成的影响及其作用机制。方法 24只雄性新西兰大耳白家兔,按体重随机分为3组,分别饲以正常基础饲料、高脂饲料(含96%基础饲料、0.5%胆固醇、3.5%猪油)、黑米皮饲料(含 91%基础饲料、0.5%胆固醇、3.5%猪油、5%黑米皮),实验期为 60d。用图像分析法测定各组家兔主动脉脂质斑块面积,并分析家兔氧化与抗氧化状态。结果 黑米皮实验家兔的主动脉壁斑块面积较高脂组低66%(P<0.001);黑米皮组实验家兔的主动脉壁8-ohdG含量和血清及主动脉壁中MDA水平也低于高脂组(P<0.05 );而红细胞及主动脉壁中SOD水平和血清α-生育酚含量在两个处理组之间差异无显著性。结论 膳食黑米皮可以抑制高脂诱导的家兔动脉粥样硬化形成,其机制可能与之降低机体氧化应激水平及过氧化脂质生成有关。 相似文献
18.
目的 探讨儿童颈椎间盘钙化症的影像表现及诊断价值,并提高对本病的认识。方法 回顾分析16例儿童颈椎钙化性椎间盘病的影像表现。结果 16例患均行颈椎平片检查,5例行CT扫描并作了三维重建,8例行MRI检查。16例平片均显示了椎间盘钙化灶,均为单发,CT平扫加三维重建显示4例钙化呈卵圆形,1例钙化为不规则形。MRI检查不仅显示了椎间盘内改变还清晰显示了病变相邻椎体边缘信号改变,在T1、T2加权像上呈低信号。结论 平片检查可以显示椎间盘钙化;CT平扫加三维重建能清晰显示了钙化灶的大小、形态;MRI检查在显示受累椎体及周围组织的改变方面明显优于CT和平片。 相似文献
19.
20.
术后胆漏和继发胆管狭窄的内镜治疗 总被引:1,自引:1,他引:0
胆漏和继发胆管狭窄是严重的外科并发症,传统的治疗方法是再次开腹手术,但再手术并发症多,死亡率高。而内镜胆管造影不仅可明确诊断,且内镜下治疗具有安全、疗效肯定、创伤小和并发症少等优点,可作为大多数胆漏和胆管狭窄患者首选治疗方法。 相似文献